The CRISPR/Cas9 system derived from bacterial adaptive immune systems is one of the most powerful genome editing technology. It is a single-guide RNA (sgRNA) and Cas9 nuclease-based RNA-guided genome editing tool. The sgRNA enables Cas9 to recognize and cut a specific target DNA sequence by base-pairing with it. This results in double strand breaks (DSBs), which cause cell repair mechanisms and mutations at or near the DSB sites. The application of CRISPR/Cas9 technology has grown from altering the gene in cells to organisms as a result of extensive research. One of the hottest topics in cancer treatment is CRISPR/Cas9 due to its potential use in gene therapy. Different CRISPR/Cas9-mediated cancer therapy concepts, such as manipulating tumor-related genes, tumor immunotherapy, modeling tumors for research, and overcoming anti-cancer drug resistance, are well-established in various cancer types.
The CRISPR-Cas9 system's greatest benefits are its ease of use and broad applicability in genome modifications of nearly all tested biological systems, including cell lines, stem cells, yeasts, worms, insects, rodents, and mammals. To direct the CRISPR-Cas9 to cut the target DNA at the intended location, only a corresponding 20 nucleotide gRNA is required for a targetable DNA site. The repair of the damaged DNA ends occurs either through NHEJ to produce indels, which have been used to produce random genomic mutations, or through HDR in the presence of donor oligonucleotides or DNA fragments containing homologous sequences flanking the DSB sites to produce precise site-directed nucleotide or large gene replacements, which produce targeted gene mutations or corrections.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V52328 | BRD0539 | 1403838-79-8 | BRD0539 is a inhibitor of CRISPR-Cas9. |
|
V52324 | BRD7586 | 895460-70-5 | BRD7586 is a cell-penetrating/penetrable small molecule inhibitor of SpCas9. |
|
V75890 | Cas9-IN-1 | 2866499-55-8 | Cas9-IN-1 is a potent Cas9 inhibitor (IC50=7.02 μM) that works via binding to apo-Cas9 to prevent the formation of Cas9:gRNA complexes. |
|
V55754 | Cas9-IN-3 | 2322051-02-3 | Cas9-IN-3 is a novel Cas9 inhibitor (IC50=28 μM). Gene editing has been transformed in a multitude of species by the CRISPR/Cas pathway. |
|
V13089 | SCR7 pyrazine | 14892-97-8 | SCR7 pyrazine is a DNA ligase IV (DNA ligase IV) inhibitor that blocks nonhomologous end joining (NHEJ) in a ligase IV-dependent manner. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
